Reuters logo
BRIEF-Bluebird Bio Inc initiates ‍expansion cohort of CRB-401 Phase 1 study of bb2121
2017年9月13日 / 中午12点16分 / 2 个月前

BRIEF-Bluebird Bio Inc initiates ‍expansion cohort of CRB-401 Phase 1 study of bb2121

Sept 13 (Reuters) - bluebird bio Inc

* bluebird bio Inc - ‍expansion cohort of crb-401 phase 1 study of bb2121, an anti-BCMA CAR T therapy, has been initiated​

* bluebird bio Inc - ‍bluebird bio and Celgene Corp are jointly developing bb2121​ Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below